Form 4: Foghorn Therapeutics Director Adam Koppel Acquires 16,000 Stock Options
SEC Form 4
Director Adam Koppel acquired 16,000 stock options in Foghorn Therapeutics Inc. on June 26, 2024, according to a Form 4 filing.
Summary
- On June 26, 2024, Adam Koppel, a director of Foghorn Therapeutics Inc., acquired 16,000 stock options with an exercise price of $5.52.
- These options become exercisable starting June 26, 2025, and expire on June 25, 2034.
- The transaction was reported in a Form 4 filing with the SEC on June 28, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is an option grant, which is part of standard compensation.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers regarding their holdings in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 06/21/2024 | Date of Power of Attorney execution. |
| 06/26/2024 | Date of the transaction: Adam Koppel acquired 16,000 stock options. |
| 06/26/2025 | Options become exercisable. |
| 06/25/2034 | Expiration date of the stock options. |
| 06/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.